3SBio Inc.

167 articles about 3SBio Inc.

• 3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

  3/22/2023

  Chinese leading biopharmaceutical company 3SBio announced its 2022 annual results.

• 3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

  8/26/2021

  Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results.

• 3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth

  3/31/2021

  Chinese leading biopharmaceutical company 3SBio unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones.

• 3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

  11/23/2020

  Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company" ), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of Sobi TM , and has

• 3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry

  9/1/2020

  According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings for August 26th 2020,   3SBio has been upgraded to A status, surpassing that of 78% of companies in the global biotechnology industry. MSCI ESG ratings focus on ESG issues that have a substantial impact on the industry at the environmental, social

• 3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

  3/31/2020

  Chinese leading biopharmaceutical company 3SBio released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursement lists.

• 3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research

  3/1/2020

  MPM Capital and Dana-Farber Cancer Institute have jointly announced on February 26, 2020 the successful closing of the MPM Oncology Innovations Fund with $100M in capital, and the Dana-Farber Innovations Research Fund with more than $26M in pledged donations.

• 

  BioSpace Global Roundup, Nov. 21

  11/21/2019

  Companies from across the globe provide updates on their businesses and pipelines.

• 3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

  11/18/2019

  PSGL-1, a novel target for immunotherapy, can induce macrophage reprogramming and activate a coordinated anti-tumor inflammatory response

• 3SBio's MSCI ESG Rating Upgraded to BBB, Ranking at the Forefront of the Global Biotechnology Industry

  9/11/2019

  According to Morgan Stanley Capital International's latest set of ESG ratings, 3SBio has been upgraded to BBB status, surpassing that of 61% of companies in the global biotechnology industry.

• 3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China

  3/3/2019

  3SBio Inc. and Taiwan Liposome Company, Ltd. announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX™ technology platform in the therapeutic areas of oncology and severe infectious diseases.

• 3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

  2/11/2019

  3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc. ("Verseau") announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers.

• 3SBio and Samsung Bioepis enter biosimilar collaboration agreement

  1/7/2019

  3SBio Inc. announced today that it has entered into a collaboration agreement with Samsung Bioepis Co., Ltd. for the clinical development and commercialization of multiple biosimilar candidates developed by Samsung Bioepis, including SB8 Bevacizumab biosimilar candidate ("SB8") in Mainland China (excluding Hong Kong, Macau and Taiwan). 

• Samsung Bioepis Partners with 3SBio to Expand Biosimilar Business into China

  1/6/2019

  Samsung Bioepis’ rapidly growing biosimilar business to expand into Chinese market through partnership with 3SBio, bringing together Samsung Bioepis’ proven development platform with 3SBio’s strong commercialization platform

• 3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China

  1/10/2018

  3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.

• 3SBio Pays $290 Million For Therapure's CDMO Biz

  9/5/2017

• 3SBio Acquires CDMO Business From Canada's Therapure For $290 Million

  9/5/2017

• 3SBio Will Market Eli Lilly's Recombinant Insulin In China

  5/18/2017

• 3SBio Appoints Dr. Zhenping Zhu As President Of Research & Development And Chief Scientific Officer

  1/9/2017

• 3SBio Pays $100 Million To Market Two AstraZeneca PLC Diabetes Drugs In China

  10/12/2016